淋巴瘤培训课.pptx

淋巴瘤的诊治规范和放疗进展;淋巴瘤治疗策略 放疗的规范 诊治进展;霍奇金淋巴瘤的诊治策略;霍奇金淋巴瘤的诊断;HL的组织学亚型;HL治疗模式的演变;淋巴瘤放射治疗的发展;结节性淋巴细胞为主型霍奇金淋巴瘤（NLPHL）的治疗;NLPHL的疗效;NLPHL的治疗研究;CHL的治疗策略决定 “Risk Adapted Treatment”;HL的预后因素;CHL的治疗策略;CHL的治疗策略;非霍奇金淋巴瘤的诊治策略;淋巴瘤分类原则;Survival of non-Hodgkin lymphoma subtypes according to the REAL classification (Blood 1997;89:3909-18);;弥漫大B细胞淋巴瘤;DLBCL的预后亚群;5 Year OS (Pre-R);Factor ;IPI vs. mIPI : 3y OS;DLBCL的化疗方案;SWOG 0014: R-CHOP-RT for Limited Disease Aggressive Histology;SWOG 0014: Limited Disease Aggressive Histology: Historical Comparison;Radiotherapy for DLBCL in Rituximab era;DLBCL的治疗策略;滤泡淋巴瘤;滤泡性淋巴瘤;早期FL的治疗;NK/T细胞淋巴瘤;NK/T细胞淋巴瘤;鼻型NK/T细胞淋巴瘤特点;NK/T细胞淋巴瘤的临床研究亚硝脲类药物加入化疗的结果;预后因素的研究;局部累及范围的研究;靶区范围的研究;07’ ASTRO;放疗剂量的研究;鼻NK/T细胞淋巴瘤的治疗推荐;结外边缘区B细胞淋巴瘤;Pinotti G,Leuk Lymphoma 1997,Zucca E, Blood 2003 ;胃MALT淋巴瘤的治疗小结;淋巴瘤放疗面临的挑战;早期CHL治疗中放疗的问题;早期CHL的RCT的荟萃分析;Extensive radiation versus less extensive radiation in stage I-II HL;Radiotherapy alone or with chemotherapy in stage I-II HL;荟萃分析的小结;早期CHL治疗中放疗面临的问题;放射野的变化;;Involved node radiotherapy (INRT)EORTC H10;Patterns of failure for INRT in early stage DLBCL;放射剂量的考虑;Dose considerations for combined modality in HL;GHSG HD10 (CS I/IIA, favorable, n=1191);HD10, final result - chemotherapy;Engert A et al, NEJM 2010;363:640-52;Engert A et al, NEJM 2010;363:640-52;HD10 conclusions for early stage, favorable HL;Dose reduction in NHL ;Aggressive NHL;能否省略放疗？;Chemotherapy vs. Radiotherapy (NCIC HD.6);Survival of NCIC HD.6 ;Cause of Death;Tata cancer centre randomized study ABVD×6 vs. ABVD ×6+RT (n=179);MSKCC randomized study in early stageABVD×6 vs. ABVD ×6+RT;放化疗的长期毒性;治疗的长期毒性;利妥昔单抗时代下弥漫大B细胞淋巴瘤的放疗;Radiotherapy for DLBCL in Rituximab era;Radiotherapy for DLBCL in Rituximab era;Results;JCO, 2010;28(27):4170-76;Radiotherapy for DLBCL in Rituximab era;小结;利妥昔单抗时代的淋巴瘤放疗;淋巴瘤放疗的靶区;淋巴瘤的放疗靶区及剂量;累及野设计的原则04’ ASTRO共识;累及野设计的原则04’ ASTRO共识;PET在淋巴瘤诊治中的应用;PET/CT在淋巴瘤的应用;FDG-PET用于淋巴瘤的分期和疗效评价的原则;PET/CT在放疗中的应用;放疗技术的进步;AP/PA;RT with different technique for lymphoma; RT fo